Skip to content

Surgical Suction Aspirates Fluorescence Measurement

Surgical Suction Aspirates Fluorescence Measurement

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06736470
Acronym
ATM GBM
Enrollment
25
Registered
2024-12-16
Start date
2023-02-07
Completion date
2026-01-01
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gliomas, High-grade Glioma

Keywords

aspirate tissue monitoring, high-grade glioma, 5-ALA, fluorescence-guided surgery, neurosurgery

Brief summary

Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. Surgeons use 5-aminolevulinic acid (5-ALA) drug-induced fluorescence to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are used to remove cancerous tissues, but so far the suction aspirate tissues have not been routinely used in tissue detection. This single-center observational study compares experts' visual detection of 5-ALA-induced fluorescence and fluorescence detected from the surgical suction waste. The fluorescence from the suction waste will not be reported back to the surgeon.

Detailed description

During glioma surgery, the diffuse boundary between healthy tissue and tumor is localized using 5-ALA drug-enhanced fluorescence of cancer cells. Visual fluorescence-based tissue recognition technique using 5-ALA has been shown to improve the rate of tumor removal and slow disease progression. To see the fluorescence typical of cancer, a special light source is needed in the operating microscope. In typical blue light, the fluorescence is visible, but it is more difficult detect anatomical landmarks, such as cerebral blood vessels and cranial nerves, which makes them vulnerable to injuries. Tumor cells can also be unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Unintended tumor remnants are frequent even though many other auxiliary techniques such as MRI guidance, neuronavigation, ultrasound and neurophysiological monitoring are used. This single center observational study investigates a novel medical device's performance to detect 5-ALA (PpIX) fluorescence from the surgical suction waste. The fluorescence detected by the device is compared to expert's visual evaluation of fluorescence using an operating microscope. The comparison includes the device's feedback, operating videos under blue and white light, anatomical location and the results of histopathological analysis. In total twenty-five (n=25) patients referred for resection surgery for suspected glioma or its recurrence at the Kuopio University Hospital. The patients are prescribed oral 5-ALA preoperatively according to the institution's practices and the suspected disease. Due to reasons not related to this study (lack of indication), some patients are not administered with 5-ALA. These patients are control patients providing reference data from brain tissues without exogenous fluorescent drugs to verify the device's safety and performance. Informed written consent will be obtained from patients to participate in the study on the new surgical device. The clinical trial is approved by the local research ethics committees and approved by the Finnish Medicines Agency (Fimea). The investigated device is not CE-marked.

Interventions

None listed

Sponsors

Marginum Ltd.
CollaboratorINDUSTRY
Kuopio University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to neurosurgery department for surgical resection of a potential glioma * Aged 18 years old or older * Informed consent obtained

Exclusion criteria

* Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled,,

Design outcomes

Primary

MeasureTime frameDescription
Visual fluorescence1 day (during surgical operation)Operating surgeon's evaluation of the presence of visual fluorescence in each scene. The expert panel's opinion of the presence of visual fluorescence in each scene of the operating video.
Fluorescence detected by the intestigational device1 day (during surgical operation)Fluorescence detected by the investigational device is compared against expert's visual detection.

Countries

Finland

Contacts

Primary ContactSami Puustinen, PhD
sami.puustinen@marginum.com+358442190767
Backup ContactAntti-Pekka Elomaa, Docent
antti-pekka.elomaa@pshyvinvointialue.fi

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026